All News

Moore, a past voting member of the ACIP, is unsure how the CDC will respond to adding "speculative concerns" to a piece of information given to every person who recieves a vaccine.

The approval is based on phase 3 trials showing durable IGF-1 control, symptom relief, and a favorable safety profile among adults with acromegaly.

Your daily dose of the clinical news you may have missed.

William Grady, MD, talks about the latest research in colorectal cancer, including treatments targeting senescent cells that contribute to tumor formation.

Moore, president and CEO of immunize.org, has deep roots in public health and advocacy, vaccine program implementation, and immunization education.

Missing a first screening mammogram was associated with a 53% greater risk of stage III breast cancer and a 40% higher risk of mortality from the disease.

The CDC said clinicians should be aware of these trends, select treatments carefully, and strengthen prevention efforts.

Your daily dose of the clinical news you may have missed.

Patient Care tapped the rich trove of research and expert perspectives from the Revolutionizing Atopic Dermatitis 2025 conference to create a snapshot of the AD care of the future.

A study of more than 559 000 adults and 2.4 million genetic samples found that alcohol consumption of any amount increases dementia risk, challenging prior evidence of protective effects from light drinking.

The FDA has initiated approval of leucovorin calcium tablets for children with cerebral folate deficiency, which can manifest with autistic features. What is it?

New data will be shared from the PATHFINDER 2 study in asymptomatic patients and the SYMPLIFY study in patients experiencing symptoms.

Your daily dose of the clinical news you may have missed.

PODCAST: Family physician Ada Stewart, MD, shares practical strategies for cervical cancer screening and patient communication.

FDA grants Fast Track designation to etalanetug, a promising tau-targeting antibody for Alzheimer disease that could expand treatment options for the neurodegenerative disease.

The findings highlight rezpegaldesleukin's novel broad-based Treg mechanism, suggesting it may be a potent option with potential for disease modification in atopic dermatitis.

The administration has initiated a nationwide public service campaign about the potential risks as professional societies quickly disputed the claims.

Your daily dose of the clinical news you may have missed.